Vaccination with autologous tumor‐derived heat shock proteins may improve survival for GBM patients when combined with standard therapy and warrants further study. Median OS for patients with high PD‐L1 expression on myeloid cells was 18.0 months as compared to 44.7 months for patients with low PD‐L1 expression (p = 0.007). This evidence concerns the gene CD274 and glioblastoma.